Directory

>

David Bleakman

avatar

David Bleakman

President Drug Discovery and Development | PsychoGenics

United States

View contact details (it's free)

David Bleakman

Summary

David Bleakman, PhD, is a seasoned executive in the biological products industry, currently serving as President of Drug Discovery and Development at Psychogenics. With extensive experience in neuroscience and drug development, he has held various leadership roles at Eli Lilly, where he led neuroscience initiatives and contributed to multiple successful drug discoveries. David has also shared his expertise as an adjunct professor at the Icahn School of Medicine at Mount Sinai. His academic credentials include a PhD from King's College London and a post-doctoral fellowship at The University of Chicago. Known for his innovative approach, he is passionate about advancing therapeutic options in the fields of psychiatry and neurology. David's career reflects a commitment to bridging scientific research with practical applications in the pharmaceutical industry.

General

Specialist

Technical Background

Leadership Experience

Long-Term Tenure

Professional interests

Emerging Technologies

Leadership Development

Innovation

Organisational experience

Corporate Experience

Consulting Experience

David Bleakman

Work Experience

company logo

President Drug Discovery and Development at

PsychoGenics

June 2022 - Present

💼

Adjunct Professor at

Department Of Neuroscience Icahn School Of Medicine At Mount Sinai

January 2018 - Present

company logo

Chief Scientific Officer at

Redpin Therapeutics

August 2018 - March 2023

company logo

Honorary Visiting Professor, School of Physiology, Pharmacology, and Neuroscience at

University Of Bristol

January 2016 - June 2019

company logo

Vice President, CSO, Neuroscience Site Leader, New York at

Eli Lilly and Company

December 2016 - February 2018

company logo

Executive Director, Neuroscience CSO and Lilly Neuroscience Site Leader, New York at

Eli Lilly and Company

June 2014 - November 2016

company logo

Executive Director and CSO, Psychiatric Disorders Research at

Eli Lilly and Company

May 2008 - May 2014

company logo

Executive Director and CSO, Pain/Migraine Reserach and Psychiatric Disorders Research at

Eli Lilly and Company

May 2007 - April 2008

company logo

CSO Pain/Migraine Research at

Eli Lilly and Company

October 2004 - April 2007

company logo

Director, Neuroscience Division at

Eli Lilly and Company

June 2001 - October 2004

company logo

Senior Research Scientist at

Eli Lilly and Company

January 2000 - May 2001

company logo

Research Scientist at

Eli Lilly and Company

August 1997 - December 1999

company logo

Research Scientist at

Eli Lilly and Company

January 1997 - July 1997

company logo

Senior Biologist at

Eli Lilly and Company

January 1995 - December 1996

company logo

Principal Biologist at

Eli Lilly and Company

February 1993 - December 1994

Logos provided by Logo.dev

David Bleakman

Education

The University of Chicago

January 1989 - January 1993

King's College London, Doctor Of Philosophy - Phd

Frequently Asked Questions about David Bleakman

What is David Bleakman email address?

David Bleakman's primary email address is *****@bristol.ac.uk. To view the full verified email and additional contact details, sign up for free with Muraena.

What company does David Bleakman work for?

David Bleakman is a President Drug Discovery and Development at PsychoGenics, a company specializing in Scientific Research & Development Services.

Where David Bleakman graduated from?

David Bleakman holds a degree in Post-Doctoral Fellow from The University of Chicago.

How can I directly contact David Bleakman?

To contact David Bleakman directly, you can use the email address *****@bristol.ac.uk. Complete contact information is available upon registration with Muraena.

Who is David Bleakman?

David Bleakman, PhD, is a seasoned executive in the biological products industry, currently serving as President of Drug Discovery and Development at Psychogenics. With extensive experience in neuroscience and drug development, he has held various leadership roles at Eli Lilly, where he led neuroscience initiatives and contributed to multiple successful drug discoveries. David has also shared his expertise as an adjunct professor at the Icahn School of Medicine at Mount Sinai. His academic credentials include a PhD from King's College London and a post-doctoral fellowship at The University of Chicago. Known for his innovative approach, he is passionate about advancing therapeutic options in the fields of psychiatry and neurology. David's career reflects a commitment to bridging scientific research with practical applications in the pharmaceutical industry.

David`s contact details

mail

*****@bristol.ac.uk

**************@psychogenics.com

Colleagues

Sylvie Ramboz

Senior Vice President, Neurodegenerative Disorders

avatar
Mitchell Silverstein

Co Founder And Volunteer

Les Street

Vice President, Head of Medicinal Chemistry, Drug Discovery

avatar
Stephen Morairty

VP, Translational Neuroscience

avatar
Daniela Brunner

Chief Technology Officer

avatar
Kathleen Kelly

Vice President Human Resources

Christina Leahy

Vice President Quality Assurance & Regulatory Affairs

Mark Klinger

Research Scientist, Director DLAR

Mark Klinger

Vice President

View Contact details (it's free)
Request Profile Removal